EMultiple myeloma is the second most common type of hematologic cancer and is incurable. Important figures in the region alert us that, from 2012 to 2019, cases of multiple myeloma in the Dominican Republic have increased by 153%, in Panama by 173%, in Guatemala by 290% and in Costa Rica by 338%.
There are approximately 2,700 cases of multiple myeloma in Central America and the Caribbean. This condition is complex to treat, since a large number of patients become resistant to treatment and, as a consequence, are often re-diagnosed after a time.
Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important component of the immune system. The immune system is made up of several types of cells that work together to fight infection and other diseases.
The MAIA phase 3 scientific study evaluated the safety and efficacy of Daratumumab, which is a monoclonal antibody, together with lenalidomide and dexamethasone in which a reduction in the progression of disease or death was shown by 44%, significantly increasing the survival times of treated patients.
“Despite the difficulties that exist in treating patients with multiple myeloma, these new therapies are helping them with this disease that is still incurable. The mechanism of action of the molecule activates the response of the patient’s immune system to act on cancer cells, “concluded Tiago Machado, Janssen’s medical manager.
Those in the first part of the study showed that 29% of the patients who received this treatment experienced a strict complete response, compared to 20% in the group that received standard therapy. Furthermore, its use resulted in a 53% reduction in the risk of disease progression or death compared to standard therapy.